Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Mehta-Shah N, Lunning MA, Moskowitz AJ, Boruchov AM, Ruan J, Lynch P, Hamlin PA, Leonard J, Matasar MJ, Myskowski PL, Marzouk E, Nair S, Sholklapper T, Minnal V, Palomba ML, Vredenburgh J, Kumar A, Noy A, Straus DJ, Zelenetz AD, Schoder H, Rademaker J, Schaffer W, Galasso N, Ganesan N, Horwitz SM.
Mehta-Shah N, et al. Among authors: myskowski pl.
Am J Hematol. 2021 Oct 1;96(10):1211-1222. doi: 10.1002/ajh.26288. Epub 2021 Jul 29.
Am J Hematol. 2021.
PMID: 34251048
Free PMC article.
Clinical Trial.